Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
72°
Clear
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
Photos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Best of 2023
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Springworks Therapeutics Inc
(NQ:
SWTX
)
41.15
+0.52 (+1.28%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Springworks Therapeutics Inc
< Previous
1
2
3
4
Next >
SpringWorks Therapeutics to Participate in the 6th Annual Evercore ISI HealthCONx Conference
November 29, 2023
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
Why SenesTech Shares Are Trading Lower By Around 50%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
November 28, 2023
Shares of SenesTech, Inc. (NASDAQ: SNES) shares moved lower during Tuesday’s session after the company reported pricing of $5.0 million public offering.
Via
Benzinga
SpringWorks Therapeutics Inc. (NASDAQ: SWTX) Near the Top of Equities by Percentage Gain on 11/28
November 28, 2023
Via
Investor Brand Network
Analyst Ratings for SpringWorks Therapeutics
August 24, 2023
Via
Benzinga
Analyst Ratings for SpringWorks Therapeutics
July 20, 2023
Via
Benzinga
The Latest Analyst Ratings for SpringWorks Therapeutics
June 06, 2023
Via
Benzinga
SpringWorks Therapeutics: Q1 Earnings Insights
May 03, 2023
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
November 28, 2023
Via
Benzinga
SpringWorks Catapults 24% On A 'Watershed Moment' In Cancer Treatment
November 28, 2023
The company gained FDA approval for Ogsiveo, a treatment for desmoid tumors.
Via
Investor's Business Daily
Exposures
Product Safety
PDD Posts Upbeat Revenue, Joins Avidity Biosciences, SpringWorks Therapeutics And Other Big Stocks Moving Higher On Tuesday
November 28, 2023
U.S. stocks traded mixed, with the Dow Jones gaining around 10 points on Tuesday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why SpringWorks Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket
November 28, 2023
Shares of SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) surged in pre-market trading after the company reported the FDA approval of OGSIVEO (nirogacestat) as the first and only treatment for adults...
Via
Benzinga
Exposures
Product Safety
FDA Approves SpringWorks Therapeutics' Lead Therapy As First For Subtype Of Soft Tissue Sarcomas
November 28, 2023
The FDA approved SpringWorks Therapeutics Inc's (NASDAQ: SWTX) Ogsiveo (nirogacestat), an oral gamma-secretase inhibitor, for adult patients with progressing desmoid tumors who
Via
Benzinga
Exposures
Product Safety
SpringWorks Therapeutics Announces FDA Approval of OGSIVEO™ (nirogacestat) as the First and Only Treatment for Adults with Desmoid Tumors
November 27, 2023
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
HC Wainwright & Co. Maintains Buy Rating for SpringWorks Therapeutics: Here's What You Need To Know
November 20, 2023
Via
Benzinga
What's Going On With Rare Diseases-Focused SpringWorks Therapeutics Stock Today?
November 16, 2023
SpringWorks Therapeutics Inc (NASDAQ: SWTX) released topline results from its Phase 2b ReNeu trial evaluating mirdametinib, an investigational MEK inhibitor, in pediatric and adult patients with...
Via
Benzinga
SpringWorks Therapeutics Announces Positive Topline Results from the Phase 2b ReNeu Trial of Mirdametinib in NF1-PN
November 16, 2023
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
SpringWorks Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights
November 02, 2023
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
SpringWorks Therapeutics Announces Presentation of Additional Data from Phase 3 DeFi Trial of Nirogacestat in Adults with Desmoid Tumors at the 2023 CTOS Annual Meeting
November 01, 2023
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
SpringWorks Therapeutics Appoints Dr. Tai-An Lin as Chief Scientific Officer
September 11, 2023
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
SpringWorks' Investigational Cancer Treatment Is Standard Care, Analyst Unfazed By FDA Update
August 24, 2023
In March, the FDA issued SpringWorks Therapeutics Inc (NASDAQ: SWTX) with a Form 483 letter due to a failure to ensure that the analysis of an exploratory endpoint in the Phase 3 DeFi trial, which...
Via
Benzinga
Exposures
Product Safety
SpringWorks Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights
August 02, 2023
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
SpringWorks Therapeutics to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference
June 07, 2023
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
SpringWorks Therapeutics Announces PDUFA Date Extension for Nirogacestat NDA
June 05, 2023
FDA Extending PDUFA Date by Three Months to Allow More Time to Complete Their Review; New PDUFA Date Set to November 27, 2023
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
Neurofibromatosis Treatment Market Value Expected to Reach $27 Billion By End Of 2029
June 01, 2023
EQNX::TICKER_START (NASDAQ:KTTA),(NASDAQ:SWTX),(NASDAQ:DAWN),(NASDAQ:VSTM),(NASDAQ:KNTE) EQNX::TICKER_END
Via
FinancialNewsMedia
SpringWorks Therapeutics Announces Full Enrollment of Phase 2 Trial Evaluating Nirogacestat in Patients with Ovarian Granulosa Cell Tumors
May 30, 2023
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
SpringWorks Therapeutics Announces Presentation of Additional Data from Phase 3 DeFi Trial of Nirogacestat in Adults with Desmoid Tumors at the 2023 ASCO Annual Meeting
May 25, 2023
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
SpringWorks Therapeutics to Participate in the TD Cowen 4th Annual Oncology Innovation Summit
May 24, 2023
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
SpringWorks Therapeutics Announces Clinical Data Presentations of Nirogacestat in Combination with BCMA-Directed Therapies at the European Hematology Association 2023 Congress
May 11, 2023
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
SpringWorks Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights
May 03, 2023
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
SpringWorks Therapeutics to Participate in the Bank of America Securities 2023 Health Care Conference
May 02, 2023
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.